– La Fundación Gates selecciona casi 50 proyectos globales de salud y desarrollo que contribuirán a dar forma al acceso equitativo a la IA El llamamiento global para la innovación liderada localmente ayudará a construir una base de evidencia para el uso de modelos de lenguaje grande de…
Month: August 2023
Encouraging CBD regulatory progress in Congress Net revenue of $16.0M vs. $18.9M YoY Cash increased to $61.7M LOUISVILLE, Colo., Aug. 10, 2023 /PRNewswire/ – (TSX: CWEB) (OTCQX: CWBHF), Charlotte’s Web Holdings, Inc. (“Charlotte’s Web” or the “Company”), the market leader in full spectrum…
Dosed first patient in Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors Nominated additional oncology target as part of the Company’s collaboration with Moderna to develop in-vivo targeted CAR-M therapies…
SAN JOSE, Calif., Aug. 10, 2023 /PRNewswire/ — ACL Digital has joined forces with Lekha Wireless, an expert in access technologies such as 5G NR, LTE, WiMAX, MANET SDR, and more. This collaboration aims to provide cutting-edge wireless connectivity solutions, specifically targeting 5G…
VANCOUVER, BC, Aug. 10, 2023 /PRNewswire/ – Nevada King Gold Corp. (TSXV: NKG) (OTCQX: NKGFF) (“Nevada King” or the “Company”) is pleased to announce assay results from four vertical reverse circulation (“RC”) holes recently completed at its Atlanta Gold Mine Project located 264km…
TORONTO, Aug. 10, 2023 /PRNewswire/ — Sabio Holdings Inc. (TSXV: SBIO) (OTCQX: SABOF) (the “Company” or “Sabio”), a leading provider of Connected TV (“CTV”) and over-the-top (“OTT”) advertising platforms validated by performance, is pleased to announce that it will host an investor…
~30-40% of ED patients do not respond to PDE5i treatment Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5i Successfully co-formulated bremelanotide with a PDE5i Phase 2 clinical study in PDE5i non-responder ED patients…
ODD is in addition to Three FDA Fast Track Designations Genprex expects to dose the first patient in the Acclaim-3 clinical trial in the fourth quarter of 2023 AUSTIN, Texas, Aug. 10, 2023 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene…
Q2 revenue down 3.9%; down 4.5% in constant currency; organic revenue down 2.2% in constant currency Q2 gross profit down 8.3%; GP rate, 19.8%, down 90 bps year-over-year due primarily to lower permanent placement fees as customer full-time hiring decelerates Q2 operating earnings of $6.2…
Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J., Aug. 10, 2023 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases…